nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—PTGS2—pancreatic cancer	0.219	1	CbGaD
Celecoxib—ORM1—Erlotinib—pancreatic cancer	0.0682	0.18	CbGbCtD
Celecoxib—ABCC4—Fluorouracil—pancreatic cancer	0.0671	0.177	CbGbCtD
Celecoxib—ABCC4—Sunitinib—pancreatic cancer	0.051	0.135	CbGbCtD
Celecoxib—ALB—Erlotinib—pancreatic cancer	0.0287	0.0757	CbGbCtD
Celecoxib—ALB—Irinotecan—pancreatic cancer	0.0259	0.0684	CbGbCtD
Celecoxib—ALB—Fluorouracil—pancreatic cancer	0.0249	0.0656	CbGbCtD
Celecoxib—CYP2C9—Tamoxifen—pancreatic cancer	0.0182	0.048	CbGbCtD
Celecoxib—CYP2D6—Tamoxifen—pancreatic cancer	0.0166	0.0439	CbGbCtD
Celecoxib—CYP2D6—Erlotinib—pancreatic cancer	0.0142	0.0373	CbGbCtD
Celecoxib—CYP2C9—Fluorouracil—pancreatic cancer	0.0134	0.0354	CbGbCtD
Celecoxib—CYP3A4—Tamoxifen—pancreatic cancer	0.0106	0.0279	CbGbCtD
Celecoxib—CYP3A4—Erlotinib—pancreatic cancer	0.009	0.0237	CbGbCtD
Celecoxib—CYP3A4—Irinotecan—pancreatic cancer	0.00813	0.0214	CbGbCtD
Celecoxib—CYP2D6—Doxorubicin—pancreatic cancer	0.00698	0.0184	CbGbCtD
Celecoxib—ORM1—bile—pancreatic cancer	0.00637	0.215	CbGeAlD
Celecoxib—CYP3A4—Docetaxel—pancreatic cancer	0.00596	0.0157	CbGbCtD
Celecoxib—CYP3A4—Sunitinib—pancreatic cancer	0.00593	0.0156	CbGbCtD
Celecoxib—CYP3A4—Doxorubicin—pancreatic cancer	0.00444	0.0117	CbGbCtD
Celecoxib—CA9—gall bladder—pancreatic cancer	0.00301	0.102	CbGeAlD
Celecoxib—PDPK1—digestive system—pancreatic cancer	0.00216	0.0729	CbGeAlD
Celecoxib—CA9—islet of Langerhans—pancreatic cancer	0.00197	0.0666	CbGeAlD
Celecoxib—ORM1—gall bladder—pancreatic cancer	0.00177	0.0596	CbGeAlD
Celecoxib—ALB—gall bladder—pancreatic cancer	0.00155	0.0523	CbGeAlD
Celecoxib—CA9—digestive system—pancreatic cancer	0.00119	0.04	CbGeAlD
Celecoxib—MAPK14—digestive system—pancreatic cancer	0.00116	0.039	CbGeAlD
Celecoxib—CA2—gall bladder—pancreatic cancer	0.00114	0.0386	CbGeAlD
Celecoxib—CA5B—pancreas—pancreatic cancer	0.000921	0.0311	CbGeAlD
Celecoxib—CA4—islet of Langerhans—pancreatic cancer	0.000904	0.0305	CbGeAlD
Celecoxib—CA12—digestive system—pancreatic cancer	0.000877	0.0296	CbGeAlD
Celecoxib—PTGS2—gall bladder—pancreatic cancer	0.000845	0.0285	CbGeAlD
Celecoxib—CA2—islet of Langerhans—pancreatic cancer	0.00075	0.0253	CbGeAlD
Celecoxib—ABCC4—pancreas—pancreatic cancer	0.000692	0.0233	CbGeAlD
Celecoxib—Etoricoxib—PTGS2—pancreatic cancer	0.000671	1	CrCbGaD
Celecoxib—ABCC4—digestive system—pancreatic cancer	0.000591	0.0199	CbGeAlD
Celecoxib—PTGS2—islet of Langerhans—pancreatic cancer	0.000554	0.0187	CbGeAlD
Celecoxib—CA4—digestive system—pancreatic cancer	0.000543	0.0183	CbGeAlD
Celecoxib—CA2—pancreas—pancreatic cancer	0.000527	0.0178	CbGeAlD
Celecoxib—CA2—digestive system—pancreatic cancer	0.00045	0.0152	CbGeAlD
Celecoxib—PTGS2—pancreas—pancreatic cancer	0.000389	0.0131	CbGeAlD
Celecoxib—CYP2C9—digestive system—pancreatic cancer	0.000381	0.0128	CbGeAlD
Celecoxib—PTGS2—digestive system—pancreatic cancer	0.000332	0.0112	CbGeAlD
Celecoxib—CYP3A4—digestive system—pancreatic cancer	0.00029	0.0098	CbGeAlD
Celecoxib—CYP2D6—digestive system—pancreatic cancer	0.000286	0.00964	CbGeAlD
Celecoxib—Myalgia—Docetaxel—pancreatic cancer	8.49e-05	0.000388	CcSEcCtD
Celecoxib—Nausea—Sunitinib—pancreatic cancer	8.49e-05	0.000388	CcSEcCtD
Celecoxib—Pancytopenia—Doxorubicin—pancreatic cancer	8.48e-05	0.000387	CcSEcCtD
Celecoxib—Asthenia—Irinotecan—pancreatic cancer	8.44e-05	0.000386	CcSEcCtD
Celecoxib—Neuropathy peripheral—Epirubicin—pancreatic cancer	8.43e-05	0.000385	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	8.43e-05	0.000385	CcSEcCtD
Celecoxib—Stomatitis—Epirubicin—pancreatic cancer	8.39e-05	0.000383	CcSEcCtD
Celecoxib—Jaundice—Epirubicin—pancreatic cancer	8.39e-05	0.000383	CcSEcCtD
Celecoxib—Urinary tract infection—Epirubicin—pancreatic cancer	8.36e-05	0.000382	CcSEcCtD
Celecoxib—Conjunctivitis—Epirubicin—pancreatic cancer	8.36e-05	0.000382	CcSEcCtD
Celecoxib—Dysuria—Doxorubicin—pancreatic cancer	8.35e-05	0.000381	CcSEcCtD
Celecoxib—Hypersensitivity—Fluorouracil—pancreatic cancer	8.31e-05	0.000379	CcSEcCtD
Celecoxib—Dry mouth—Docetaxel—pancreatic cancer	8.3e-05	0.000379	CcSEcCtD
Celecoxib—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	8.3e-05	0.000379	CcSEcCtD
Celecoxib—Pollakiuria—Doxorubicin—pancreatic cancer	8.25e-05	0.000377	CcSEcCtD
Celecoxib—Asthenia—Gemcitabine—pancreatic cancer	8.23e-05	0.000376	CcSEcCtD
Celecoxib—Haematuria—Epirubicin—pancreatic cancer	8.2e-05	0.000375	CcSEcCtD
Celecoxib—Confusional state—Docetaxel—pancreatic cancer	8.2e-05	0.000375	CcSEcCtD
Celecoxib—Photosensitivity reaction—Doxorubicin—pancreatic cancer	8.15e-05	0.000372	CcSEcCtD
Celecoxib—Hepatobiliary disease—Epirubicin—pancreatic cancer	8.14e-05	0.000372	CcSEcCtD
Celecoxib—Oedema—Docetaxel—pancreatic cancer	8.14e-05	0.000372	CcSEcCtD
Celecoxib—Anaphylactic shock—Docetaxel—pancreatic cancer	8.14e-05	0.000372	CcSEcCtD
Celecoxib—Weight increased—Doxorubicin—pancreatic cancer	8.13e-05	0.000371	CcSEcCtD
Celecoxib—Epistaxis—Epirubicin—pancreatic cancer	8.12e-05	0.000371	CcSEcCtD
Celecoxib—Pruritus—Gemcitabine—pancreatic cancer	8.11e-05	0.000371	CcSEcCtD
Celecoxib—Infection—Docetaxel—pancreatic cancer	8.08e-05	0.000369	CcSEcCtD
Celecoxib—Sinusitis—Epirubicin—pancreatic cancer	8.07e-05	0.000369	CcSEcCtD
Celecoxib—Hyperglycaemia—Doxorubicin—pancreatic cancer	8.06e-05	0.000368	CcSEcCtD
Celecoxib—Diarrhoea—Irinotecan—pancreatic cancer	8.05e-05	0.000368	CcSEcCtD
Celecoxib—Agranulocytosis—Epirubicin—pancreatic cancer	8.03e-05	0.000367	CcSEcCtD
Celecoxib—Pneumonia—Doxorubicin—pancreatic cancer	8.01e-05	0.000366	CcSEcCtD
Celecoxib—Shock—Docetaxel—pancreatic cancer	8.01e-05	0.000366	CcSEcCtD
Celecoxib—Nervous system disorder—Docetaxel—pancreatic cancer	7.98e-05	0.000364	CcSEcCtD
Celecoxib—Pruritus—Fluorouracil—pancreatic cancer	7.98e-05	0.000364	CcSEcCtD
Celecoxib—Thrombocytopenia—Docetaxel—pancreatic cancer	7.97e-05	0.000364	CcSEcCtD
Celecoxib—Infestation NOS—Doxorubicin—pancreatic cancer	7.96e-05	0.000364	CcSEcCtD
Celecoxib—Infestation—Doxorubicin—pancreatic cancer	7.96e-05	0.000364	CcSEcCtD
Celecoxib—Tachycardia—Docetaxel—pancreatic cancer	7.94e-05	0.000363	CcSEcCtD
Celecoxib—Skin disorder—Docetaxel—pancreatic cancer	7.9e-05	0.000361	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	7.89e-05	0.000361	CcSEcCtD
Celecoxib—Diarrhoea—Gemcitabine—pancreatic cancer	7.84e-05	0.000358	CcSEcCtD
Celecoxib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	7.8e-05	0.000356	CcSEcCtD
Celecoxib—Dizziness—Irinotecan—pancreatic cancer	7.78e-05	0.000356	CcSEcCtD
Celecoxib—Haemoglobin—Epirubicin—pancreatic cancer	7.76e-05	0.000355	CcSEcCtD
Celecoxib—Stomatitis—Doxorubicin—pancreatic cancer	7.76e-05	0.000354	CcSEcCtD
Celecoxib—Jaundice—Doxorubicin—pancreatic cancer	7.76e-05	0.000354	CcSEcCtD
Celecoxib—Anorexia—Docetaxel—pancreatic cancer	7.76e-05	0.000354	CcSEcCtD
Celecoxib—Rhinitis—Epirubicin—pancreatic cancer	7.74e-05	0.000354	CcSEcCtD
Celecoxib—Conjunctivitis—Doxorubicin—pancreatic cancer	7.74e-05	0.000354	CcSEcCtD
Celecoxib—Urinary tract infection—Doxorubicin—pancreatic cancer	7.74e-05	0.000354	CcSEcCtD
Celecoxib—Haemorrhage—Epirubicin—pancreatic cancer	7.72e-05	0.000353	CcSEcCtD
Celecoxib—Hepatitis—Epirubicin—pancreatic cancer	7.72e-05	0.000353	CcSEcCtD
Celecoxib—Diarrhoea—Fluorouracil—pancreatic cancer	7.71e-05	0.000352	CcSEcCtD
Celecoxib—Hypoaesthesia—Epirubicin—pancreatic cancer	7.69e-05	0.000351	CcSEcCtD
Celecoxib—Pharyngitis—Epirubicin—pancreatic cancer	7.67e-05	0.00035	CcSEcCtD
Celecoxib—Urinary tract disorder—Epirubicin—pancreatic cancer	7.63e-05	0.000348	CcSEcCtD
Celecoxib—Oedema peripheral—Epirubicin—pancreatic cancer	7.61e-05	0.000348	CcSEcCtD
Celecoxib—Haematuria—Doxorubicin—pancreatic cancer	7.59e-05	0.000347	CcSEcCtD
Celecoxib—Connective tissue disorder—Epirubicin—pancreatic cancer	7.59e-05	0.000347	CcSEcCtD
Celecoxib—Urethral disorder—Epirubicin—pancreatic cancer	7.57e-05	0.000346	CcSEcCtD
Celecoxib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	7.53e-05	0.000344	CcSEcCtD
Celecoxib—Epistaxis—Doxorubicin—pancreatic cancer	7.51e-05	0.000343	CcSEcCtD
Celecoxib—Vomiting—Irinotecan—pancreatic cancer	7.48e-05	0.000342	CcSEcCtD
Celecoxib—Sinusitis—Doxorubicin—pancreatic cancer	7.47e-05	0.000341	CcSEcCtD
Celecoxib—Dizziness—Fluorouracil—pancreatic cancer	7.45e-05	0.000341	CcSEcCtD
Celecoxib—Agranulocytosis—Doxorubicin—pancreatic cancer	7.43e-05	0.000339	CcSEcCtD
Celecoxib—Rash—Irinotecan—pancreatic cancer	7.42e-05	0.000339	CcSEcCtD
Celecoxib—Dermatitis—Irinotecan—pancreatic cancer	7.41e-05	0.000339	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	7.41e-05	0.000339	CcSEcCtD
Celecoxib—Headache—Irinotecan—pancreatic cancer	7.37e-05	0.000337	CcSEcCtD
Celecoxib—Insomnia—Docetaxel—pancreatic cancer	7.36e-05	0.000336	CcSEcCtD
Celecoxib—Paraesthesia—Docetaxel—pancreatic cancer	7.31e-05	0.000334	CcSEcCtD
Celecoxib—Erythema multiforme—Epirubicin—pancreatic cancer	7.3e-05	0.000334	CcSEcCtD
Celecoxib—Vomiting—Gemcitabine—pancreatic cancer	7.29e-05	0.000333	CcSEcCtD
Celecoxib—Dyspnoea—Docetaxel—pancreatic cancer	7.25e-05	0.000331	CcSEcCtD
Celecoxib—Somnolence—Docetaxel—pancreatic cancer	7.23e-05	0.00033	CcSEcCtD
Celecoxib—Rash—Gemcitabine—pancreatic cancer	7.23e-05	0.00033	CcSEcCtD
Celecoxib—Dermatitis—Gemcitabine—pancreatic cancer	7.22e-05	0.00033	CcSEcCtD
Celecoxib—Eye disorder—Epirubicin—pancreatic cancer	7.22e-05	0.00033	CcSEcCtD
Celecoxib—Tinnitus—Epirubicin—pancreatic cancer	7.2e-05	0.000329	CcSEcCtD
Celecoxib—Haemoglobin—Doxorubicin—pancreatic cancer	7.18e-05	0.000328	CcSEcCtD
Celecoxib—Headache—Gemcitabine—pancreatic cancer	7.18e-05	0.000328	CcSEcCtD
Celecoxib—Flushing—Epirubicin—pancreatic cancer	7.17e-05	0.000327	CcSEcCtD
Celecoxib—Cardiac disorder—Epirubicin—pancreatic cancer	7.17e-05	0.000327	CcSEcCtD
Celecoxib—Vomiting—Fluorouracil—pancreatic cancer	7.17e-05	0.000327	CcSEcCtD
Celecoxib—Rhinitis—Doxorubicin—pancreatic cancer	7.17e-05	0.000327	CcSEcCtD
Celecoxib—Dyspepsia—Docetaxel—pancreatic cancer	7.16e-05	0.000327	CcSEcCtD
Celecoxib—Hepatitis—Doxorubicin—pancreatic cancer	7.15e-05	0.000326	CcSEcCtD
Celecoxib—Haemorrhage—Doxorubicin—pancreatic cancer	7.15e-05	0.000326	CcSEcCtD
Celecoxib—Hypoaesthesia—Doxorubicin—pancreatic cancer	7.11e-05	0.000325	CcSEcCtD
Celecoxib—Rash—Fluorouracil—pancreatic cancer	7.11e-05	0.000325	CcSEcCtD
Celecoxib—Dermatitis—Fluorouracil—pancreatic cancer	7.1e-05	0.000324	CcSEcCtD
Celecoxib—Pharyngitis—Doxorubicin—pancreatic cancer	7.09e-05	0.000324	CcSEcCtD
Celecoxib—Decreased appetite—Docetaxel—pancreatic cancer	7.07e-05	0.000323	CcSEcCtD
Celecoxib—Headache—Fluorouracil—pancreatic cancer	7.06e-05	0.000323	CcSEcCtD
Celecoxib—Urinary tract disorder—Doxorubicin—pancreatic cancer	7.06e-05	0.000322	CcSEcCtD
Celecoxib—Oedema peripheral—Doxorubicin—pancreatic cancer	7.04e-05	0.000322	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	7.02e-05	0.000321	CcSEcCtD
Celecoxib—Connective tissue disorder—Doxorubicin—pancreatic cancer	7.02e-05	0.000321	CcSEcCtD
Celecoxib—Fatigue—Docetaxel—pancreatic cancer	7.01e-05	0.00032	CcSEcCtD
Celecoxib—Angiopathy—Epirubicin—pancreatic cancer	7.01e-05	0.00032	CcSEcCtD
Celecoxib—Urethral disorder—Doxorubicin—pancreatic cancer	7.01e-05	0.00032	CcSEcCtD
Celecoxib—Nausea—Irinotecan—pancreatic cancer	6.99e-05	0.000319	CcSEcCtD
Celecoxib—Immune system disorder—Epirubicin—pancreatic cancer	6.98e-05	0.000319	CcSEcCtD
Celecoxib—Mediastinal disorder—Epirubicin—pancreatic cancer	6.96e-05	0.000318	CcSEcCtD
Celecoxib—Constipation—Docetaxel—pancreatic cancer	6.96e-05	0.000318	CcSEcCtD
Celecoxib—Arrhythmia—Epirubicin—pancreatic cancer	6.9e-05	0.000315	CcSEcCtD
Celecoxib—Alopecia—Epirubicin—pancreatic cancer	6.83e-05	0.000312	CcSEcCtD
Celecoxib—Nausea—Gemcitabine—pancreatic cancer	6.81e-05	0.000311	CcSEcCtD
Celecoxib—Mental disorder—Epirubicin—pancreatic cancer	6.77e-05	0.000309	CcSEcCtD
Celecoxib—Erythema multiforme—Doxorubicin—pancreatic cancer	6.76e-05	0.000309	CcSEcCtD
Celecoxib—Feeling abnormal—Docetaxel—pancreatic cancer	6.7e-05	0.000306	CcSEcCtD
Celecoxib—Nausea—Fluorouracil—pancreatic cancer	6.7e-05	0.000306	CcSEcCtD
Celecoxib—Eye disorder—Doxorubicin—pancreatic cancer	6.68e-05	0.000305	CcSEcCtD
Celecoxib—Tinnitus—Doxorubicin—pancreatic cancer	6.66e-05	0.000304	CcSEcCtD
Celecoxib—Gastrointestinal pain—Docetaxel—pancreatic cancer	6.65e-05	0.000304	CcSEcCtD
Celecoxib—Flushing—Doxorubicin—pancreatic cancer	6.63e-05	0.000303	CcSEcCtD
Celecoxib—Cardiac disorder—Doxorubicin—pancreatic cancer	6.63e-05	0.000303	CcSEcCtD
Celecoxib—Flatulence—Epirubicin—pancreatic cancer	6.63e-05	0.000303	CcSEcCtD
Celecoxib—Tension—Epirubicin—pancreatic cancer	6.6e-05	0.000301	CcSEcCtD
Celecoxib—Dysgeusia—Epirubicin—pancreatic cancer	6.59e-05	0.000301	CcSEcCtD
Celecoxib—Nervousness—Epirubicin—pancreatic cancer	6.53e-05	0.000298	CcSEcCtD
Celecoxib—Back pain—Epirubicin—pancreatic cancer	6.5e-05	0.000297	CcSEcCtD
Celecoxib—Angiopathy—Doxorubicin—pancreatic cancer	6.48e-05	0.000296	CcSEcCtD
Celecoxib—Muscle spasms—Epirubicin—pancreatic cancer	6.47e-05	0.000295	CcSEcCtD
Celecoxib—Immune system disorder—Doxorubicin—pancreatic cancer	6.46e-05	0.000295	CcSEcCtD
Celecoxib—Mediastinal disorder—Doxorubicin—pancreatic cancer	6.44e-05	0.000294	CcSEcCtD
Celecoxib—Abdominal pain—Docetaxel—pancreatic cancer	6.43e-05	0.000294	CcSEcCtD
Celecoxib—Body temperature increased—Docetaxel—pancreatic cancer	6.43e-05	0.000294	CcSEcCtD
Celecoxib—Arrhythmia—Doxorubicin—pancreatic cancer	6.39e-05	0.000292	CcSEcCtD
Celecoxib—Vision blurred—Epirubicin—pancreatic cancer	6.34e-05	0.000289	CcSEcCtD
Celecoxib—Alopecia—Doxorubicin—pancreatic cancer	6.32e-05	0.000288	CcSEcCtD
Celecoxib—Mental disorder—Doxorubicin—pancreatic cancer	6.26e-05	0.000286	CcSEcCtD
Celecoxib—Anaemia—Epirubicin—pancreatic cancer	6.22e-05	0.000284	CcSEcCtD
Celecoxib—Flatulence—Doxorubicin—pancreatic cancer	6.13e-05	0.00028	CcSEcCtD
Celecoxib—Tension—Doxorubicin—pancreatic cancer	6.11e-05	0.000279	CcSEcCtD
Celecoxib—Dysgeusia—Doxorubicin—pancreatic cancer	6.09e-05	0.000278	CcSEcCtD
Celecoxib—Nervousness—Doxorubicin—pancreatic cancer	6.04e-05	0.000276	CcSEcCtD
Celecoxib—Vertigo—Epirubicin—pancreatic cancer	6.04e-05	0.000276	CcSEcCtD
Celecoxib—Syncope—Epirubicin—pancreatic cancer	6.03e-05	0.000275	CcSEcCtD
Celecoxib—Leukopenia—Epirubicin—pancreatic cancer	6.02e-05	0.000275	CcSEcCtD
Celecoxib—Back pain—Doxorubicin—pancreatic cancer	6.02e-05	0.000275	CcSEcCtD
Celecoxib—Hypersensitivity—Docetaxel—pancreatic cancer	5.99e-05	0.000274	CcSEcCtD
Celecoxib—Muscle spasms—Doxorubicin—pancreatic cancer	5.98e-05	0.000273	CcSEcCtD
Celecoxib—Palpitations—Epirubicin—pancreatic cancer	5.94e-05	0.000271	CcSEcCtD
Celecoxib—Loss of consciousness—Epirubicin—pancreatic cancer	5.91e-05	0.00027	CcSEcCtD
Celecoxib—Cough—Epirubicin—pancreatic cancer	5.87e-05	0.000268	CcSEcCtD
Celecoxib—Vision blurred—Doxorubicin—pancreatic cancer	5.86e-05	0.000268	CcSEcCtD
Celecoxib—Asthenia—Docetaxel—pancreatic cancer	5.84e-05	0.000267	CcSEcCtD
Celecoxib—Hypertension—Epirubicin—pancreatic cancer	5.81e-05	0.000265	CcSEcCtD
Celecoxib—Pruritus—Docetaxel—pancreatic cancer	5.76e-05	0.000263	CcSEcCtD
Celecoxib—Anaemia—Doxorubicin—pancreatic cancer	5.75e-05	0.000263	CcSEcCtD
Celecoxib—Arthralgia—Epirubicin—pancreatic cancer	5.72e-05	0.000261	CcSEcCtD
Celecoxib—Chest pain—Epirubicin—pancreatic cancer	5.72e-05	0.000261	CcSEcCtD
Celecoxib—Myalgia—Epirubicin—pancreatic cancer	5.72e-05	0.000261	CcSEcCtD
Celecoxib—Anxiety—Epirubicin—pancreatic cancer	5.71e-05	0.000261	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	5.69e-05	0.00026	CcSEcCtD
Celecoxib—Dry mouth—Epirubicin—pancreatic cancer	5.6e-05	0.000256	CcSEcCtD
Celecoxib—Vertigo—Doxorubicin—pancreatic cancer	5.59e-05	0.000255	CcSEcCtD
Celecoxib—Syncope—Doxorubicin—pancreatic cancer	5.58e-05	0.000255	CcSEcCtD
Celecoxib—Leukopenia—Doxorubicin—pancreatic cancer	5.57e-05	0.000254	CcSEcCtD
Celecoxib—Diarrhoea—Docetaxel—pancreatic cancer	5.57e-05	0.000254	CcSEcCtD
Celecoxib—Confusional state—Epirubicin—pancreatic cancer	5.53e-05	0.000253	CcSEcCtD
Celecoxib—Palpitations—Doxorubicin—pancreatic cancer	5.5e-05	0.000251	CcSEcCtD
Celecoxib—Oedema—Epirubicin—pancreatic cancer	5.49e-05	0.000251	CcSEcCtD
Celecoxib—Anaphylactic shock—Epirubicin—pancreatic cancer	5.49e-05	0.000251	CcSEcCtD
Celecoxib—Loss of consciousness—Doxorubicin—pancreatic cancer	5.47e-05	0.00025	CcSEcCtD
Celecoxib—Infection—Epirubicin—pancreatic cancer	5.45e-05	0.000249	CcSEcCtD
Celecoxib—Cough—Doxorubicin—pancreatic cancer	5.43e-05	0.000248	CcSEcCtD
Celecoxib—Shock—Epirubicin—pancreatic cancer	5.4e-05	0.000247	CcSEcCtD
Celecoxib—Nervous system disorder—Epirubicin—pancreatic cancer	5.38e-05	0.000246	CcSEcCtD
Celecoxib—Dizziness—Docetaxel—pancreatic cancer	5.38e-05	0.000246	CcSEcCtD
Celecoxib—Thrombocytopenia—Epirubicin—pancreatic cancer	5.37e-05	0.000245	CcSEcCtD
Celecoxib—Hypertension—Doxorubicin—pancreatic cancer	5.37e-05	0.000245	CcSEcCtD
Celecoxib—Tachycardia—Epirubicin—pancreatic cancer	5.36e-05	0.000245	CcSEcCtD
Celecoxib—Skin disorder—Epirubicin—pancreatic cancer	5.33e-05	0.000243	CcSEcCtD
Celecoxib—Hyperhidrosis—Epirubicin—pancreatic cancer	5.31e-05	0.000242	CcSEcCtD
Celecoxib—Arthralgia—Doxorubicin—pancreatic cancer	5.3e-05	0.000242	CcSEcCtD
Celecoxib—Chest pain—Doxorubicin—pancreatic cancer	5.3e-05	0.000242	CcSEcCtD
Celecoxib—Myalgia—Doxorubicin—pancreatic cancer	5.3e-05	0.000242	CcSEcCtD
Celecoxib—Anxiety—Doxorubicin—pancreatic cancer	5.28e-05	0.000241	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	5.26e-05	0.00024	CcSEcCtD
Celecoxib—Anorexia—Epirubicin—pancreatic cancer	5.23e-05	0.000239	CcSEcCtD
Celecoxib—Dry mouth—Doxorubicin—pancreatic cancer	5.18e-05	0.000237	CcSEcCtD
Celecoxib—Vomiting—Docetaxel—pancreatic cancer	5.17e-05	0.000236	CcSEcCtD
Celecoxib—Rash—Docetaxel—pancreatic cancer	5.13e-05	0.000234	CcSEcCtD
Celecoxib—Dermatitis—Docetaxel—pancreatic cancer	5.13e-05	0.000234	CcSEcCtD
Celecoxib—Confusional state—Doxorubicin—pancreatic cancer	5.12e-05	0.000234	CcSEcCtD
Celecoxib—Headache—Docetaxel—pancreatic cancer	5.1e-05	0.000233	CcSEcCtD
Celecoxib—Anaphylactic shock—Doxorubicin—pancreatic cancer	5.08e-05	0.000232	CcSEcCtD
Celecoxib—Oedema—Doxorubicin—pancreatic cancer	5.08e-05	0.000232	CcSEcCtD
Celecoxib—Infection—Doxorubicin—pancreatic cancer	5.04e-05	0.00023	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	5e-05	0.000228	CcSEcCtD
Celecoxib—Shock—Doxorubicin—pancreatic cancer	5e-05	0.000228	CcSEcCtD
Celecoxib—Nervous system disorder—Doxorubicin—pancreatic cancer	4.98e-05	0.000227	CcSEcCtD
Celecoxib—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.97e-05	0.000227	CcSEcCtD
Celecoxib—Insomnia—Epirubicin—pancreatic cancer	4.96e-05	0.000227	CcSEcCtD
Celecoxib—Tachycardia—Doxorubicin—pancreatic cancer	4.96e-05	0.000226	CcSEcCtD
Celecoxib—Skin disorder—Doxorubicin—pancreatic cancer	4.93e-05	0.000225	CcSEcCtD
Celecoxib—Paraesthesia—Epirubicin—pancreatic cancer	4.93e-05	0.000225	CcSEcCtD
Celecoxib—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.91e-05	0.000224	CcSEcCtD
Celecoxib—Dyspnoea—Epirubicin—pancreatic cancer	4.89e-05	0.000223	CcSEcCtD
Celecoxib—Somnolence—Epirubicin—pancreatic cancer	4.88e-05	0.000223	CcSEcCtD
Celecoxib—Anorexia—Doxorubicin—pancreatic cancer	4.84e-05	0.000221	CcSEcCtD
Celecoxib—Nausea—Docetaxel—pancreatic cancer	4.83e-05	0.000221	CcSEcCtD
Celecoxib—Dyspepsia—Epirubicin—pancreatic cancer	4.83e-05	0.000221	CcSEcCtD
Celecoxib—Decreased appetite—Epirubicin—pancreatic cancer	4.77e-05	0.000218	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	4.74e-05	0.000216	CcSEcCtD
Celecoxib—Fatigue—Epirubicin—pancreatic cancer	4.73e-05	0.000216	CcSEcCtD
Celecoxib—Constipation—Epirubicin—pancreatic cancer	4.69e-05	0.000214	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	4.63e-05	0.000211	CcSEcCtD
Celecoxib—Insomnia—Doxorubicin—pancreatic cancer	4.59e-05	0.00021	CcSEcCtD
Celecoxib—Paraesthesia—Doxorubicin—pancreatic cancer	4.56e-05	0.000208	CcSEcCtD
Celecoxib—Dyspnoea—Doxorubicin—pancreatic cancer	4.53e-05	0.000207	CcSEcCtD
Celecoxib—Feeling abnormal—Epirubicin—pancreatic cancer	4.52e-05	0.000207	CcSEcCtD
Celecoxib—Somnolence—Doxorubicin—pancreatic cancer	4.51e-05	0.000206	CcSEcCtD
Celecoxib—Gastrointestinal pain—Epirubicin—pancreatic cancer	4.49e-05	0.000205	CcSEcCtD
Celecoxib—Dyspepsia—Doxorubicin—pancreatic cancer	4.47e-05	0.000204	CcSEcCtD
Celecoxib—Decreased appetite—Doxorubicin—pancreatic cancer	4.41e-05	0.000202	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	4.38e-05	0.0002	CcSEcCtD
Celecoxib—Fatigue—Doxorubicin—pancreatic cancer	4.38e-05	0.0002	CcSEcCtD
Celecoxib—Urticaria—Epirubicin—pancreatic cancer	4.36e-05	0.000199	CcSEcCtD
Celecoxib—Constipation—Doxorubicin—pancreatic cancer	4.34e-05	0.000198	CcSEcCtD
Celecoxib—Abdominal pain—Epirubicin—pancreatic cancer	4.34e-05	0.000198	CcSEcCtD
Celecoxib—Body temperature increased—Epirubicin—pancreatic cancer	4.34e-05	0.000198	CcSEcCtD
Celecoxib—Feeling abnormal—Doxorubicin—pancreatic cancer	4.18e-05	0.000191	CcSEcCtD
Celecoxib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	4.15e-05	0.00019	CcSEcCtD
Celecoxib—Hypersensitivity—Epirubicin—pancreatic cancer	4.04e-05	0.000185	CcSEcCtD
Celecoxib—Urticaria—Doxorubicin—pancreatic cancer	4.03e-05	0.000184	CcSEcCtD
Celecoxib—Body temperature increased—Doxorubicin—pancreatic cancer	4.01e-05	0.000183	CcSEcCtD
Celecoxib—Abdominal pain—Doxorubicin—pancreatic cancer	4.01e-05	0.000183	CcSEcCtD
Celecoxib—Asthenia—Epirubicin—pancreatic cancer	3.94e-05	0.00018	CcSEcCtD
Celecoxib—Pruritus—Epirubicin—pancreatic cancer	3.88e-05	0.000177	CcSEcCtD
Celecoxib—Diarrhoea—Epirubicin—pancreatic cancer	3.75e-05	0.000172	CcSEcCtD
Celecoxib—Hypersensitivity—Doxorubicin—pancreatic cancer	3.74e-05	0.000171	CcSEcCtD
Celecoxib—Asthenia—Doxorubicin—pancreatic cancer	3.64e-05	0.000166	CcSEcCtD
Celecoxib—Dizziness—Epirubicin—pancreatic cancer	3.63e-05	0.000166	CcSEcCtD
Celecoxib—Pruritus—Doxorubicin—pancreatic cancer	3.59e-05	0.000164	CcSEcCtD
Celecoxib—Vomiting—Epirubicin—pancreatic cancer	3.49e-05	0.000159	CcSEcCtD
Celecoxib—Diarrhoea—Doxorubicin—pancreatic cancer	3.47e-05	0.000159	CcSEcCtD
Celecoxib—Rash—Epirubicin—pancreatic cancer	3.46e-05	0.000158	CcSEcCtD
Celecoxib—Dermatitis—Epirubicin—pancreatic cancer	3.46e-05	0.000158	CcSEcCtD
Celecoxib—Headache—Epirubicin—pancreatic cancer	3.44e-05	0.000157	CcSEcCtD
Celecoxib—Dizziness—Doxorubicin—pancreatic cancer	3.36e-05	0.000153	CcSEcCtD
Celecoxib—Nausea—Epirubicin—pancreatic cancer	3.26e-05	0.000149	CcSEcCtD
Celecoxib—Vomiting—Doxorubicin—pancreatic cancer	3.23e-05	0.000147	CcSEcCtD
Celecoxib—Rash—Doxorubicin—pancreatic cancer	3.2e-05	0.000146	CcSEcCtD
Celecoxib—Dermatitis—Doxorubicin—pancreatic cancer	3.2e-05	0.000146	CcSEcCtD
Celecoxib—Headache—Doxorubicin—pancreatic cancer	3.18e-05	0.000145	CcSEcCtD
Celecoxib—Nausea—Doxorubicin—pancreatic cancer	3.02e-05	0.000138	CcSEcCtD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.1e-05	7.21e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EGF—pancreatic cancer	1.09e-05	7.17e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—KRAS—pancreatic cancer	1.09e-05	7.17e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—TYMP—pancreatic cancer	1.09e-05	7.16e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CG—pancreatic cancer	1.09e-05	7.15e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TP53—pancreatic cancer	1.09e-05	7.14e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.09e-05	7.14e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PIK3CB—pancreatic cancer	1.09e-05	7.13e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—KRAS—pancreatic cancer	1.08e-05	7.1e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—MYC—pancreatic cancer	1.08e-05	7.09e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—TGFB1—pancreatic cancer	1.08e-05	7.08e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.08e-05	7.08e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—EGF—pancreatic cancer	1.08e-05	7.07e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTGS2—pancreatic cancer	1.08e-05	7.06e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GLP1R—pancreatic cancer	1.08e-05	7.05e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—KRAS—pancreatic cancer	1.07e-05	7.04e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—PPARG—pancreatic cancer	1.06e-05	6.96e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—EGFR—pancreatic cancer	1.06e-05	6.94e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—DPYD—pancreatic cancer	1.06e-05	6.93e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PIK3CB—pancreatic cancer	1.06e-05	6.92e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—HRAS—pancreatic cancer	1.04e-05	6.83e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—PIK3CA—pancreatic cancer	1.03e-05	6.74e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—EGFR—pancreatic cancer	1.02e-05	6.7e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDH1—pancreatic cancer	1.02e-05	6.68e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CXCL8—pancreatic cancer	1.01e-05	6.65e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—HRAS—pancreatic cancer	1.01e-05	6.6e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—SLC2A2—pancreatic cancer	1e-05	6.58e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—KRAS—pancreatic cancer	1e-05	6.55e-05	CbGpPWpGaD
Celecoxib—CA14—Metabolism—AKT1—pancreatic cancer	9.97e-06	6.53e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—PIK3CA—pancreatic cancer	9.96e-06	6.52e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	9.94e-06	6.51e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SMAD4—pancreatic cancer	9.93e-06	6.51e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	9.89e-06	6.48e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—PIK3CA—pancreatic cancer	9.87e-06	6.46e-05	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—AKT1—pancreatic cancer	9.8e-06	6.42e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CD—pancreatic cancer	9.74e-06	6.38e-05	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—AKT1—pancreatic cancer	9.72e-06	6.37e-05	CbGpPWpGaD
Celecoxib—CA6—Metabolism—AKT1—pancreatic cancer	9.72e-06	6.37e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CASP3—pancreatic cancer	9.71e-06	6.36e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HES1—pancreatic cancer	9.7e-06	6.35e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—KRAS—pancreatic cancer	9.67e-06	6.33e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CD44—pancreatic cancer	9.61e-06	6.3e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CD—pancreatic cancer	9.6e-06	6.29e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	9.59e-06	6.28e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TP53—pancreatic cancer	9.54e-06	6.25e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PRSS1—pancreatic cancer	9.51e-06	6.23e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCND1—pancreatic cancer	9.45e-06	6.19e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	9.41e-06	6.17e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTEN—pancreatic cancer	9.4e-06	6.16e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CTNNB1—pancreatic cancer	9.36e-06	6.13e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—HRAS—pancreatic cancer	9.31e-06	6.1e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GCG—pancreatic cancer	9.22e-06	6.04e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HRAS—pancreatic cancer	9.21e-06	6.03e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—AKT1—pancreatic cancer	9.21e-06	6.03e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PIK3CA—pancreatic cancer	9.19e-06	6.02e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MMP9—pancreatic cancer	9.18e-06	6.01e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—HRAS—pancreatic cancer	9.13e-06	5.98e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PTEN—pancreatic cancer	9.12e-06	5.98e-05	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—AKT1—pancreatic cancer	9.07e-06	5.94e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SMAD4—pancreatic cancer	9.06e-06	5.94e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	9.01e-06	5.91e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—AKT1—pancreatic cancer	8.9e-06	5.83e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—PIK3CA—pancreatic cancer	8.88e-06	5.82e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GLP1R—pancreatic cancer	8.88e-06	5.82e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HES1—pancreatic cancer	8.85e-06	5.8e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GLP1R—pancreatic cancer	8.81e-06	5.77e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—DPYD—pancreatic cancer	8.74e-06	5.72e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	8.74e-06	5.72e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—STK11—pancreatic cancer	8.67e-06	5.68e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—DPYD—pancreatic cancer	8.66e-06	5.68e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—HRAS—pancreatic cancer	8.5e-06	5.57e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TERT—pancreatic cancer	8.5e-06	5.57e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CB—pancreatic cancer	8.49e-06	5.56e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—SRC—pancreatic cancer	8.46e-06	5.54e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—AKT1—pancreatic cancer	8.41e-06	5.51e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CB—pancreatic cancer	8.37e-06	5.48e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	8.29e-06	5.43e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ARG2—pancreatic cancer	8.24e-06	5.4e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—VEGFA—pancreatic cancer	8.24e-06	5.4e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	8.22e-06	5.39e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HRAS—pancreatic cancer	8.22e-06	5.38e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—AKT1—pancreatic cancer	8.22e-06	5.38e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PIK3CA—pancreatic cancer	8.2e-06	5.38e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—STAT3—pancreatic cancer	8.16e-06	5.35e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—NRAS—pancreatic cancer	8.14e-06	5.33e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	8.14e-06	5.33e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.13e-06	5.33e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—AKT1—pancreatic cancer	8.13e-06	5.33e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HIF1A—pancreatic cancer	8.13e-06	5.33e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TSC2—pancreatic cancer	8.11e-06	5.31e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	8.08e-06	5.29e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—AKT1—pancreatic cancer	8.06e-06	5.28e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—APOE—pancreatic cancer	7.93e-06	5.2e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PIK3CA—pancreatic cancer	7.87e-06	5.15e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	7.85e-06	5.14e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CD44—pancreatic cancer	7.78e-06	5.1e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KDR—pancreatic cancer	7.77e-06	5.09e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TERT—pancreatic cancer	7.75e-06	5.08e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.62e-06	4.99e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MYC—pancreatic cancer	7.58e-06	4.97e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TGFB1—pancreatic cancer	7.56e-06	4.96e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.55e-06	4.94e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CTNNB1—pancreatic cancer	7.52e-06	4.93e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—AKT1—pancreatic cancer	7.51e-06	4.92e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GCG—pancreatic cancer	7.46e-06	4.88e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—TYMS—pancreatic cancer	7.45e-06	4.88e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—EGFR—pancreatic cancer	7.42e-06	4.86e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HIF1A—pancreatic cancer	7.42e-06	4.86e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TSC2—pancreatic cancer	7.4e-06	4.85e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NFKBIA—pancreatic cancer	7.39e-06	4.84e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PTEN—pancreatic cancer	7.33e-06	4.8e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NOTCH1—pancreatic cancer	7.32e-06	4.8e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—AKT1—pancreatic cancer	7.26e-06	4.75e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—APOE—pancreatic cancer	7.24e-06	4.74e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—TYMP—pancreatic cancer	7.2e-06	4.72e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CG—pancreatic cancer	7.16e-06	4.69e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	7.15e-06	4.69e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EGF—pancreatic cancer	7.08e-06	4.64e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—STK11—pancreatic cancer	7.01e-06	4.59e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KRAS—pancreatic cancer	7.01e-06	4.59e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—SRC—pancreatic cancer	6.8e-06	4.46e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—SRC—pancreatic cancer	6.7e-06	4.39e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—AKT1—pancreatic cancer	6.7e-06	4.39e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOTCH1—pancreatic cancer	6.68e-06	4.38e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PIK3CA—pancreatic cancer	6.63e-06	4.34e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.58e-06	4.31e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—STAT3—pancreatic cancer	6.56e-06	4.3e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NRAS—pancreatic cancer	6.54e-06	4.29e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—VEGFA—pancreatic cancer	6.53e-06	4.28e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EGF—pancreatic cancer	6.46e-06	4.23e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NRAS—pancreatic cancer	6.45e-06	4.22e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PIK3CA—pancreatic cancer	6.44e-06	4.22e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—AKT1—pancreatic cancer	6.43e-06	4.21e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CD44—pancreatic cancer	6.42e-06	4.21e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CD44—pancreatic cancer	6.37e-06	4.17e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CD—pancreatic cancer	6.3e-06	4.12e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	6.23e-06	4.08e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—pancreatic cancer	6.23e-06	4.08e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	6.18e-06	4.05e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GCG—pancreatic cancer	6.16e-06	4.03e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GCG—pancreatic cancer	6.1e-06	4e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—APOE—pancreatic cancer	6.06e-06	3.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MYC—pancreatic cancer	6.06e-06	3.97e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—TYMS—pancreatic cancer	6.03e-06	3.95e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TGFB1—pancreatic cancer	5.99e-06	3.93e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EGFR—pancreatic cancer	5.96e-06	3.91e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—HRAS—pancreatic cancer	5.96e-06	3.9e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	5.81e-06	3.8e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—STK11—pancreatic cancer	5.79e-06	3.79e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CD—pancreatic cancer	5.74e-06	3.76e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—STK11—pancreatic cancer	5.74e-06	3.76e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.74e-06	3.76e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—DPYD—pancreatic cancer	5.71e-06	3.74e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KRAS—pancreatic cancer	5.63e-06	3.69e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—KRAS—pancreatic cancer	5.55e-06	3.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CB—pancreatic cancer	5.49e-06	3.59e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CG—pancreatic cancer	5.47e-06	3.58e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	5.42e-06	3.55e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—AKT1—pancreatic cancer	5.42e-06	3.55e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.39e-06	3.53e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PPARG—pancreatic cancer	5.28e-06	3.46e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCL8—pancreatic cancer	5.27e-06	3.45e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—AKT1—pancreatic cancer	5.26e-06	3.44e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CA—pancreatic cancer	5.17e-06	3.39e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CA—pancreatic cancer	5.1e-06	3.34e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CASP3—pancreatic cancer	5.05e-06	3.31e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CB—pancreatic cancer	5.01e-06	3.28e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—TYMS—pancreatic cancer	4.98e-06	3.26e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—TYMS—pancreatic cancer	4.94e-06	3.23e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—pancreatic cancer	4.93e-06	3.23e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCND1—pancreatic cancer	4.91e-06	3.22e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—APOE—pancreatic cancer	4.9e-06	3.21e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CTNNB1—pancreatic cancer	4.86e-06	3.19e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CD—pancreatic cancer	4.81e-06	3.15e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HRAS—pancreatic cancer	4.79e-06	3.14e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MMP9—pancreatic cancer	4.77e-06	3.12e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTEN—pancreatic cancer	4.74e-06	3.11e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—HRAS—pancreatic cancer	4.72e-06	3.09e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.64e-06	3.04e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CTNNB1—pancreatic cancer	4.44e-06	2.91e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CG—pancreatic cancer	4.43e-06	2.9e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SRC—pancreatic cancer	4.4e-06	2.88e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PTEN—pancreatic cancer	4.33e-06	2.83e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—VEGFA—pancreatic cancer	4.28e-06	2.81e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PPARG—pancreatic cancer	4.27e-06	2.8e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—STAT3—pancreatic cancer	4.24e-06	2.78e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NRAS—pancreatic cancer	4.23e-06	2.77e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—AKT1—pancreatic cancer	4.23e-06	2.77e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—AKT1—pancreatic cancer	4.2e-06	2.75e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CD44—pancreatic cancer	4.2e-06	2.75e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CB—pancreatic cancer	4.19e-06	2.75e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—AKT1—pancreatic cancer	4.17e-06	2.73e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—APOE—pancreatic cancer	4.05e-06	2.65e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GCG—pancreatic cancer	4.03e-06	2.64e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—APOE—pancreatic cancer	4.01e-06	2.63e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SRC—pancreatic cancer	4.01e-06	2.63e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MYC—pancreatic cancer	3.94e-06	2.58e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TGFB1—pancreatic cancer	3.93e-06	2.58e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CD—pancreatic cancer	3.89e-06	2.55e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—STAT3—pancreatic cancer	3.87e-06	2.53e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NRAS—pancreatic cancer	3.86e-06	2.53e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EGFR—pancreatic cancer	3.85e-06	2.52e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.8e-06	2.49e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—STK11—pancreatic cancer	3.78e-06	2.48e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	3.65e-06	2.39e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KRAS—pancreatic cancer	3.64e-06	2.39e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	3.62e-06	2.37e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PTEN—pancreatic cancer	3.62e-06	2.37e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MYC—pancreatic cancer	3.59e-06	2.35e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TGFB1—pancreatic cancer	3.59e-06	2.35e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PPARG—pancreatic cancer	3.53e-06	2.31e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EGFR—pancreatic cancer	3.52e-06	2.3e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PPARG—pancreatic cancer	3.5e-06	2.29e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CB—pancreatic cancer	3.39e-06	2.22e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS2—pancreatic cancer	3.36e-06	2.2e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CA—pancreatic cancer	3.34e-06	2.19e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KRAS—pancreatic cancer	3.32e-06	2.18e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.26e-06	2.13e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—pancreatic cancer	3.24e-06	2.12e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.21e-06	2.1e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	3.19e-06	2.09e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HRAS—pancreatic cancer	3.09e-06	2.03e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CA—pancreatic cancer	3.05e-06	2e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTEN—pancreatic cancer	2.93e-06	1.92e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HRAS—pancreatic cancer	2.82e-06	1.85e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	2.8e-06	1.83e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	2.78e-06	1.82e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS2—pancreatic cancer	2.77e-06	1.82e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS2—pancreatic cancer	2.75e-06	1.8e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—AKT1—pancreatic cancer	2.73e-06	1.79e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—APOE—pancreatic cancer	2.65e-06	1.73e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CA—pancreatic cancer	2.56e-06	1.67e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—AKT1—pancreatic cancer	2.49e-06	1.63e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.42e-06	1.59e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTEN—pancreatic cancer	2.4e-06	1.57e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.39e-06	1.57e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.31e-06	1.51e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.1e-06	1.38e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—AKT1—pancreatic cancer	2.09e-06	1.37e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CA—pancreatic cancer	2.07e-06	1.35e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.83e-06	1.2e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.81e-06	1.19e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.71e-06	1.12e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	1.69e-06	1.11e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—AKT1—pancreatic cancer	1.69e-06	1.11e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.58e-06	1.04e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.39e-06	9.14e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.38e-06	9.06e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.12e-06	7.31e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AKT1—pancreatic cancer	9.12e-07	5.97e-06	CbGpPWpGaD
